Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05250037

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

Status
Recruiting
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
All
Age
8 Years
Healthy volunteers
Not accepted

Summary

This observational trial studies whether respiratory viruses are the cause of lung disease (bronchiolitis obliterans syndrome \[BOS\] or graft-versus-host disease of the lung) and changes in lung function in patients who have received a donor stem cell transplant. Patients with chronic graft-versus-host disease (cGVHD) are at higher risk of developing BOS. Studies have also shown that patients who had a respiratory viral illness early after their transplant are at higher risk of developing lung problems later on. Patients who are at risk and who already have BOS might benefit from being monitored more closely. Spirometry is a way of assessing a patient's lung function and is often used to diagnose lung disease. Spirometry measured at home with a simple handheld device may reduce the burden of performing pulmonary function testing at a facility and potentially help patients get their lung disease diagnosed and treated sooner.

Detailed description

OUTLINE: This is an observational study. Patients undergo home spirometry measurements with a portable handheld spirometer and complete questionnaires weekly, a nasal swab for viral polymerase chain reaction (PCR) surveillance every 4 weeks, and undergo blood collection and nasal swabs every 3 months for up to 2 years. (The minimum required follow-up is 1 year, but there is an optional 1 year extension period.)

Conditions

Interventions

TypeNameDescription
PROCEDUREHome spirometryUndergo spirometry measurements
PROCEDUREBiospecimen CollectionUndergo nasal and/or oral swabs, and blood collection
OTHERQuestionnaire AdministrationComplete questionnaires

Timeline

Start date
2022-03-30
Primary completion
2027-12-31
Completion
2028-06-30
First posted
2022-02-22
Last updated
2026-01-08

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT05250037. Inclusion in this directory is not an endorsement.